Business Description
EyePoint Inc. is a medical company focused on treating serious eye diseases, particularly conditions that damage the retina. Its main product in development, DURAVYU, is designed to deliver medication inside the eye over an extended period and is currently being tested in late-stage clinical trials for wet age-related macular degeneration and diabetic macular edema. The company also has an earlier-stage program, EYP-2301, which targets a different biological pathway and may offer additional treatment options for patients with retinal disease. Founded in 2000 and based in Watertown, Massachusetts, EyePoint aims to reduce the burden of frequent eye injections that many patients currently face.
